SL

Tonix Pharmaceuticals Presented New Data on Tonmya™ Suggesting Activity for Improvement in Fibromyalgia-Associated Depression Severity in an Oral Presentation at ASCP Annual Meeting

Retrieved on: 
Lundi, juin 3, 2024
MD, ITT, Anxiety, Patient, Memory, Hydrogen chloride, Grammatical mood, Society, Depression, Science, Week, Diagnosis, ASCP, MDE, Tablet, Pharmaceutical industry

CHATHAM, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, presented new data from the Phase 3 RESILIENT trial of Tonmya (TNX-102 SL, cyclobenzaprine HCl sublingual tablets) for the management of fibromyalgia in an oral presentation at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting on May 29, 2024 in Miami Beach, Fla. A copy of the presentation is available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com.

Key Points: 
  • The effect of Tonmya on depressive symptoms was studied using the Beck Depression Inventory-II (BDI-II).
  • Patients started with a baseline mean (standard deviation) for placebo of 10.0 (6.72) and Tonmya of 9.6 (6.32).
  • Tonix is a fully-integrated biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering.
  • All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements.

Tonix Pharmaceuticals Announces Two Poster Presentations of TNX-102 SL (Sublingual Cyclobenzaprine HCl) at the ASCP Annual Meeting

Retrieved on: 
Jeudi, mai 30, 2024
NDA, FDA, Trauma, Reduction, PTSD, ASD, Week, COVID, ASCP, Therapy, Disability, Infection, Cocaine, Psychiatry, New Drug Application, Sleep, Sumatriptan, ASR, Autoimmunity, CNS, OASIS, Security (finance), Tonix Pharmaceuticals, Military personnel, Insomnia, Food, Safety, Long, Research, Cancer, Fatigue, Annual report, PROMIS, Society, Cognition, Failure, Science, Fibromyalgia, Patient, Risk, Government, Breakthrough therapy, CD40L, Health, Acute stress disorder, Observation, Veteran, Central nervous system, Disease, Annual general meeting, Pharmaceutical industry

CHATHAM, N.J., May 30, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced two poster presentations at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting being held May 28-31, 2024 in Miami Beach, Fla. Copies of the presentations are available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com.

Key Points: 
  • Copies of the presentations are available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com .
  • TNX-102 SL was well tolerated with an adverse event profile comparable to prior studies and no new safety signals observed.
  • Previous trials of TNX-102 SL showed that it reduced military PTSD symptoms in as early as two weeks with favorable tolerability.
  • Randomized clinical trial of bedtime sublingual cyclobenzaprine (TNX-102 SL) in military-related PTSD and the role of sleep quality in treatment response.

Tonix Pharmaceuticals Announces Two Oral Presentations and One Poster Presentation Involving TNX-1500 (Fc-modified humanized anti-CD40L mAb) at the American Transplant Congress 2024

Retrieved on: 
Mercredi, mai 29, 2024
Security (finance), Sumatriptan, Risk, Food, NDA, FDA, Autoimmunity, Government, Breakthrough therapy, Long, CD40L, Research, Cancer, Fibromyalgia, CNS, Annual report, Therapy, Infection, Failure, Central nervous system, Cocaine, Disease, Pharmaceutical industry

TNX-102 SL is also being developed to treat acute stress reaction as well as fibromyalgia-type Long COVID.

Key Points: 
  • TNX-102 SL is also being developed to treat acute stress reaction as well as fibromyalgia-type Long COVID.
  • Tonix’s CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has Breakthrough Therapy designation.
  • Tonix also has product candidates in development in the areas of rare disease and infectious disease.
  • All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements.

Tonix Pharmaceuticals to Deliver an Oral Presentation and Present Two Posters at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

Retrieved on: 
Mercredi, mai 22, 2024
Security (finance), Sleep, Sumatriptan, Risk, Food, NDA, Disease, University, ASR, FDA, Autoimmunity, Breakthrough therapy, Government, Reduction, Long, CD40L, Research, Cancer, Annual general meeting, CBP, CNS, Fatigue, Annual report, Acute stress disorder, ASCP, Society, Anxiety, Therapy, Infection, Cognition, Failure, Central nervous system, Cocaine, Science, OASIS, Pharmaceutical industry

CHATHAM, N.J., May 22, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that the Company will deliver an oral presentation and present two posters at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting being held May 28-31, 2024 at the Loews Miami Beach Hotel in Miami Beach, Fla.

Key Points: 
  • The oral presentation will detail findings of studies of Tonmya (TNX-102 SL, sublingual cyclobenzaprine HCl) in fibromyalgia.
  • One poster will describe the Phase 2 proof of concept study of TNX-102 SL in fibromyalgia-type Long COVID.
  • TNX-102 SL is a centrally acting, non-opioid medication, which is trade named Tonmya™ for the management of fibromyalgia.
  • Copies of the Company’s presentation and posters will be available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com following the conference.

Savile Row Showcase: Broad Arrow Presents its Latest Private Sales Offering, A Handsome 1963 Mercedes-Benz 300 SL Roadster Alongside Highlights from the Upcoming July Petroliana and Memorabilia Online Auctions

Retrieved on: 
Mardi, mai 21, 2024
Online, Roadster, Partnership, Taste, Huntsman, Online auction, Private, Calendar, Collection, Sale, Diaphragm, Aluminium, Autumn, GPS, F1, Broad arrow, Mercedes-Benz, Auction

Additional highlights of the display will also include selected petroliana and memorabilia lots that will be offered via Online Auction in July and October of 2024.

Key Points: 
  • Additional highlights of the display will also include selected petroliana and memorabilia lots that will be offered via Online Auction in July and October of 2024.
  • We are excited to present this exceptional Private Sales Mercedes-Benz for consideration alongside highlights from the upcoming Petroliana and memorabilia sales.
  • Matt Coles, Petroliana and Memorabilia Specialist for Broad Arrow, states, “I am delighted to present this outstanding UK-based collection of Petroliana.
  • 1963 Mercedes-Benz Photos Courtesy of Drew Gibson, all memorabilia photos courtesy of Ian Skelton

Tonix Pharmaceuticals Announces Key Findings from Initial Phase of EVERSANA Market Opportunity Analysis for Tonmya™ for the Management of Fibromyalgia

Retrieved on: 
Mardi, mai 21, 2024
Patient, Hydrogen chloride, Tonix Pharmaceuticals, Polypharmacy, Medicare, Food, NDA, Prevalence, GTM, Diagnosis, FDA, Inflation, Database, Research, Physician, Tablet, Fatigue, Fibromyalgia, Female, Pharmaceutical industry

Tonix previously announced that EVERSANA was selected to support the launch strategy and commercial planning of Tonmya.

Key Points: 
  • Tonix previously announced that EVERSANA was selected to support the launch strategy and commercial planning of Tonmya.
  • Specifically, EVERSANA is working with Tonix to assess the fibromyalgia landscape and help plan an efficient go-to-market (GTM) strategy.
  • “The primary research and analysis conducted by EVERSANA provides valuable insights and informs the vision for the commercialization of Tonmya,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals.
  • Key findings from claims data analyses2:
    ~2.7 million adults in the U.S. currently diagnosed and treated for fibromyalgia.

Tonix Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase

Retrieved on: 
Mercredi, mai 15, 2024
Security (finance), Sumatriptan, Risk, Food, NDA, FDA, Autoimmunity, Breakthrough therapy, Government, Long, CD40L, Research, Cancer, Fibromyalgia, CNS, Annual report, Therapy, Infection, Failure, Central nervous system, Cocaine, Disease, Pharmaceutical industry

A replay of the presentation will also be available under the IR Events tab of the Tonix website at www.tonixpharma.com following the event.

Key Points: 
  • A replay of the presentation will also be available under the IR Events tab of the Tonix website at www.tonixpharma.com following the event.
  • Tonix is a fully-integrated biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering.
  • Tonix’s CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has Breakthrough Therapy designation.
  • All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements.

Fobi AI Announces Appointment of New Auditor

Retrieved on: 
Mardi, mai 7, 2024
News, AI, Partnership, MNP, MNP LLP, Cryptocurrency

VANCOUVER, BC, May 07, 2024 (GLOBE NEWSWIRE) -- Fobi AI Inc. (FOBI:TSXV) (FOBIF:OTCQB) (the "Company" or "Fobi"), an industry leader in harnessing AI and data intelligence to enable digital transformation, announces the appointment of MNP LLP (“MNP”) as Auditor of the Company effective May 6, 2024.

Key Points: 
  • VANCOUVER, BC, May 07, 2024 (GLOBE NEWSWIRE) -- Fobi AI Inc. (FOBI:TSXV) (FOBIF:OTCQB) (the "Company" or "Fobi"), an industry leader in harnessing AI and data intelligence to enable digital transformation, announces the appointment of MNP LLP (“MNP”) as Auditor of the Company effective May 6, 2024.
  • Rob Anson, CEO of Fobi AI, states: "I am pleased to announce our new partnership with MNP, a highly respected and professional audit group.
  • This appointment marks a positive milestone for our organization as we collaborate with one of the industry's leading experts in financial audits.
  • To download the Fobi Investor Experience Wallet Pass to get enhanced access to investor information about Fobi, please visit our Investor Experience page .

Simpleminers Introduces Shared Cloud Mining Business

Retrieved on: 
Vendredi, avril 26, 2024
Bitcoin, Friends, Mining, Communication, Investment, Safety, Risk, Android, IOS, Cryptocurrency

London, UK, April 26, 2024 (GLOBE NEWSWIRE) -- Simpleminers , a leading Bitcoin mining service provider, per a recent announcement, introduces a shared cloud mining business for institutional and low-income investors.

Key Points: 
  • London, UK, April 26, 2024 (GLOBE NEWSWIRE) -- Simpleminers , a leading Bitcoin mining service provider, per a recent announcement, introduces a shared cloud mining business for institutional and low-income investors.
  • “The cloud mining business can ensure that Simpleminers has a steady stream of funds to deploy computing power to increase Bitcoin production.
  • Simpleminers’ shared cloud mining business aligns with the company’s vision to simplify crypto investments, enabling new and existing customers to conveniently purchase mining contracts and earn each time new blocks are added to the network.
  • Simpleminers has partnered with some of the leading brands in the industry as it seeks to simplify crypto investments and mining.

Tonix Pharmaceuticals Announces Presentation at Planet MicroCap Showcase

Retrieved on: 
Mercredi, avril 24, 2024
FDA, CD40L, Cancer, Sumatriptan, NDA, Long, Food, Risk, Planet, Disease, Annual report, Security (finance), Cocaine, Research, CNS, Therapy, Failure, Infection, Central nervous system, Government, Breakthrough therapy, Fibromyalgia, Autoimmunity, Pharmaceutical industry

The presentation will include data from the recently reported positive Phase 3 RESILIENT trial of Tonmya™ (also known as TNX-102 SL) for the management of fibromyalgia.

Key Points: 
  • The presentation will include data from the recently reported positive Phase 3 RESILIENT trial of Tonmya™ (also known as TNX-102 SL) for the management of fibromyalgia.
  • A copy of the Company’s presentation will be available under the Presentations tab of the Tonix website at www.tonixpharma.com following the conference.
  • Additional meeting information can be found on the showcase website .
  • Tonix is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering.